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1. Introduction
   Iron is a trace element that is essential for many 
biological  processes  such as  oxygen t ransport , 
energy production and DNA synthesis[1,2]. There is 
no physiological mechanism for iron excretion in 
humans[3,4]. When iron is present in excess, it results in 
iron accumulation in tissues causing damage and cell 
death via free radical formation[5,6]. Non-transferrin 
bound iron (NTBI), and its redox active component labile 
plasma iron (LPI), appear in plasma when the transferrin 
saturation increases[7-10]. Ferritin iron accumulation is 
also elevated in extreme cases of iron overloaded to the 
formation of hemosiderin[11-13]. Levels of serum NTBI, LPI 
and ferritin have been proposed for determination of iron 
overload and evaluation of efficiency in iron chelation 
therapy[14-16]. There is a wide range of clinically used 
iron chelators available to remove iron; nonetheless, 
side effects of these drugs have been observed in some 
patients undergoing chelation therapy. Desferrioxamine 
is not orally active, has poor bioavailability, and can 
cause ocular and auditory toxicity[17,18]. Deferiprone (DFP) 
is an orally active chelator and has side effects including 
nausea, vomiting, gastrointestinal tract disturbances, 
zinc deficiency, leucopenia and thrombocytopenia[19,20]. 
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Deferasirox is another effective oral chelator associated 
with renal toxicity in some patients[21,22]. Therefore, it is 
necessary to search for additional safer orally active iron 
chelators. We have developed a novel oral bidentate iron 
chelator, 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-
methylpyridin-4-one (CM1) which is a DFP analogue and 
has a higher level of lipid solubility (Kpart=0.53)[23]. Our 
previous study showed that CM1 effectively bound both 
ferric and ferrous ions, and also efficiently decreased 
levels of plasma NTBI in vitro and in vivo[24]. Importantly, 
the compound was found to be non-toxic to peripheral 
blood mononuclear and liver cell cultures[25]. A systematic 
study on the efficacy and toxicity of CM1 has not been 
conducted. In this study, we evaluated efficacy and safety 
of the compound in mice under normal and iron overload 
conditions.
2. Materials and methods
2.1. Animals
   Young adult C57BL/6 mice aged between 6-10 weeks and 
having a body weight of (20依3) g were housed in hygienic 
cages and maintained in a clean, air-conditioned room 
under the following conditions: a 12-h day/12-h night 
cycle, a temperature of (23依1) °C and a relative humidity 
of 40%-70%. The study protocol has been approved by the 
Animal Ethical Committee of the Medical Faculty, Chiang 
Mai University, Thailand) (Reference Number-3/2554).
2.2. Iron loading and chelation treatment
   The mice (50 males and 50 females) were fed a normal 
diet and the diet supplemented with 0.2% (w/w) ferrocene 
(Fe diet) to induce iron overload over 240 d[26]. The iron-
loaded mice were then randomly subdivided into 5 
groups (10 male and 10 female mice in each group) for the 
treatments with distilled water, DFP (50 mg/kg per day) and 
CM1 (50, 100 and 200 mg/kg per day) for 180 d. The control 
groups (50 males and 50 females) were fed with normal diet 
along with the iron chelators throughout the study. 
2.3. Blood and tissue collection
   Blood samples were collected from the tail vein into 
Na-heparin capillary tubes at the beginning, 60 d and 
then every 45 d during treatment. Plasma was separated 
immediately and kept frozen −80 °C for analysis of liver 
enzymes. At the end of study, the mice were sacrificed and 
blood was collected into Na-heparin tubes from the heart 
left ventricles. Subsequently, the blood was centrifuged 
and the plasma was separated for determination of the iron 
parameters. The hearts, livers and spleens were collected 
and fixed in 10% (v/v) neutralized formalin solution for 
pathological examination.
2.4. Quantification of NTBI
   The ni tr i lotr iacet ic  acid ( NTA)  chelat ion/high 
performance liquid chromatography (HPLC) technique was 
used for plasma NTBI quantification[27]. Briefly, plasma 
was incubated with NTA solution (80 mmol/L at a final 
concentration) for 30 min at room temperature to produce 
the Fe3+-(NTA)2 complex from NTBI. After that the complex 
was filtered through a membrane (Nano-Sep®, 10-kDa 
cutoff, polysulfone type; Pall Life Sciences, Ann Arbor, MI, 
USA) at 12 000 r/min for 60 min and then analyzed using 
a non-metallic HPLC system. NTBI was fractionated on a 
glass analytical column (ChromSep-ODS1, 100 mm伊3.0 mm, 
5 µm), and eluted with mobile phase solvent (3 mmol/L 
CP22 in 20% acetonitrile/MOPS pH 7.0) at a flow rate of 1.0 
mL/min and optical density was monitored at 450 nm using 
a flow cell detector (SpecMonitor2300; LDC Milton-Roy 
Inc., Riviera Beach, FL, USA). Data analysis was conducted 
with BDS software (BarSpec Ltd., Rehovot, Israel). NTBI 
concentration represented by Fe3+-(CP22)3 peak area was 
calculated with a calibration curve constructed from Fe3+-
(NTA)2 in 80 mmol/L NTA (0-32 µmol/L).
2.5. Measurement of LPI concentration
   Redox-active LPI converts dihydrorhodamine (DHR) to 
oxidized fluorescent rhodamine, leading to an increase 
in fluorescence intensity (FI)[28]. Briefly, 20 µL of plasma 
was incubated with/without 5 mmol/L DFP at 37 °C for 30 
min and DHR solution containing ascorbic acid was then 
added (180 µL). Kinetic spectrofluorometry (λex 485 nm, λem 
538 nm) was performed immediately for 40 min at 37 °C 
with reading every 2 min. The increasing FI was followed 
and slope of the FI was plotted against the reaction time. 
A calibration curve was created from standard ferrous 
ammonium sulfate solution (0-20 µmol/L). The difference 
in the rate of DHR oxidation plus and minus DFP represents 
the redox active LPI in plasma. The LPI concentration 
was calculated from the calibration curve relating the 
difference in slope with/without DFP versus standard iron 
concentration as described above.
2.6. Measurement of plasma ferritin concentration
   Ferritin concentration was determined by ELISA kit (Cat 
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No. KA1941, Abnova, United Kingdom) according to the 
manufacturer’s instruction[29].
2.7. Measurement of hematological parameters
   The tail vein blood samples were drawn into heparin-
containing capillary tubes. Whole blood was taken 
to measure hemoglobin concentrations following the 
cyanmethemoglobin method[30]. Separated white blood 
cells and platelets were diluted with respective white 
blood cell diluting solution (1:50, v/v) and platelet diluting 
solution (1:200, v/v) (Biotechnical Co., Ltd., Bangkok, 
Thailand), and counted in a hematocytometer under light 
microscope.
2.8. Assay of liver enzyme activity 
   Activities of plasma aspartate aminotransferase (AST), 
alanine aminotransferase (ALT) and alkaline phosphatase 
(ALP) were determined spectophotometrically by using 
commercially available assay kits (Biotechnical Co., 
Ltd., Bangkok, Thailand) according to the manufacturer’s 
instruction[31,32].
2.9. Histopathological examination
   Heart, liver and spleen tissues were dissected, fixed 
immediately in 10% neutral buffered formalin and 
dehydrated with a graded series of ethyl alcohol at the 
end of study. The tissues were embedded in paraffin wax, 
sectioned and stained with hematoxylin & eosin dye. The 
tissue slides were examined under a light microscope 
by an expert pathologist and photographed with a digital 
camera.
2.10. Statistical analysis
   The results were expressed as mean依SEM. Results were 
analyzed by One-way analysis of variance (ANOVA), where 
P<0.05 were considered statistically significant.
3. Results
3.1. Effect of CM1 on NTBI and LPI levels
   Low levels of NTBI were detected in the plasma of non-
overloaded mice there being no significant different 
between the placebo and the experimental group. 
In contrast, the NTBI concentration was significantly 
increased in the plasma of the iron-overloaded mice 
fed with distilled water (35.5依2.0 µmol/L), indicating iron 
overload (Figure 1). As expected, the NTBI concentration 
was reduced as a result of treatment with DFP (50 mg/kg), 
and CM1 (50 mg/kg) (P<0.05). Levels of plasma NTBI in the 
mice after intervention with CM1 (100 and 200 mg/kg) were 
found to be lower than that at 50 mg/kg, NTBI decreasing 
with increasing CM1 in a dose-dependent manner 
(P<0.001). Similarly, plasma LPI levels were very low in the 
non-iron overloaded group and markedly increased in the 
iron-overloaded mice (Figure 2). Expectedly, chelation 
with DFP (50 mg/kg) and CM1 (100 and 200 mg/kg) for 180 
d effectively reduced the plasma LPI levels in iron-
overloaded mice, which significant difference of the LPI 
levels was not found for the different doses of CM1.
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Figure 1. Plasma NTBI concentrations of the normal diet and Fe diet-fed 
mice along with treatment of distilled water, DFP and CM1for 180 d. 
Data are expressed as mean依SEM (n=10). Group 1: Distilled water; Group 2: 
DFP 50 mg/kg; Group 3: CM1 50 mg/kg; Group 4: CM1 100 mg/kg; Group 5: 
CM1 200 mg/kg. a: P<0.05, b: P<0.001 when compared with placebo group.
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Figure 2. Plasma LPI concentrations of the normal diet and Fe diet-fed 
mice along with treatment of distilled water, DFP and CM1 for 180 d.
Data are expressed as mean依SEM (n=10). Group 1: Distilled water; Group 2: 
DFP 50 mg/kg; Group 3: CM1 50 mg/kg; Group 4: CM1 100 mg/kg; Group 5: 
CM1 200 mg/kg.
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Figure 3. Plasma ferritin concentrations of the normal diet and Fe diet-fed 
mice along with treatment of distilled water, DFP and CM1 for 180 d.
Data are expressed as mean依SEM (n=10). Group 1: Distilled water; Group 2: 
DFP 50 mg/kg; Group 3: CM1 50 mg/kg; Group 4: CM1 100 mg/kg; Group 5: 
CM1 200 mg/kg.
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3.2. Effect of CM1 on plasma ferritin concentration
   Plasma ferritin concentrations of the iron-overloaded 
mice [(16.0依0.3) µg/mL] were found to be significantly 
higher than those of the mice without iron overload [(0.4
依0.07) µg/mL]. However, the levels of plasma ferritin 
remained unchanged after 180 d of intervention with 
both DFP (50 mg/kg) and CM1 (50, 100 and 200 mg/kg) 
(Figure 3).
3.3. Effect of CM1 on hematopoietic cells
   Blood hemoglobin concentration, white blood cell and 
platelet numbers of the Fe diet-fed mice treated with 
difference doses of CM1 were not different from those 
of the none chelated Fe diet-fed mice as well as those 
of the normal diet-fed mice (Table 1). This implies that 
CM1 would not be toxic to bone marrow cells of the 
mice under normal and iron-overload conditions.
Table 1 
Hematological parameters values of the normal diet and Fe diet-fed mice treated with distilled water (DW), DFP and CM1 for 180 d. 
Days Diet Hemoglobin (g/dL) White blood cells (伊109 cells/L) Platelets (伊1012 cells/L)
DW DFP 
50 mg/
kg
CM1 
50 mg/
kg
CM1 
100 mg/
kg
CM1 
200 mg/
kg
DW DFP 
50 mg/kg
CM1 
50 mg/
kg
CM1 
100 mg/
kg
CM1 
200 mg/
kg
DW DFP 
50 mg/kg
CM1 
50 mg/
kg
CM1 
100 mg/
kg
CM1 
200 mg/
kg
0 N 16.1依0.4 17.7依0.2 17.5依0.5 19.5依0.6 18.7依0.4 2.2依1.9 2.3依1.7 1.8依1.4 2.1依2.0 2.4依1.8 3.5依0.2 3.7依0.2 3.7依0.2 3.1依2.2 3.6依0.2
Fe 18.4依0.5 17.4依0.6 19.2依1.1 19.5依0.7 17.0依0.7 2.6依0.2 3.4依0.4 2.5依0.3 3.1依0.3 3.1依0.3 4.1依0.2 3.8依0.4 3.5依0.3 3.0依0.2 3.0依0.2
60 N 16.6依0.6 17.3依0.2 15.7依0.7 15.8依0.6 15.8依0.5 3.9依1.1 2.7依0.3 2.7依0.4 2.9依0.5 2.5依0.4 3.7依0.4 3.1依0.3 3.3依0.2 3.5依0.3 4.1依0.4
Fe 14.7依0.7 14.9依0.4 16.4依0.6 17.0依0.6 16.5依0.6 4.8依0.6 4.0依0.4 3.7依0.5 3.9依0.4 4.0依0.4 3.0依0.3 2.8依0.3 2.5依0.3 2.7依0.4 2.5依0.4
105 N 17.0依0.3 18.3依0.4 18.3依0.9 17.6依0.6 18.4依0.3 3.5依0.4 5.1依0.9 4.8依1.2 3.5依0.3 5.0依1.1 2.8依0.4 2.4依0.3 2.4依0.3 2.4依0.2 2.1依0.2
Fe 15.1依0.6 16.1依0.4 15.5依0.5 15.0依0.7 15.0依0.7 4.1依0.4 4.0依0.3 3.6依0.3 4.0依0.4 4.6依0.3 2.3依0.1 2.9依0.2 2.8依0.2 2.5依0.2 2.4依0.2
150 N 17.7依1.1 18.4依0.8 19.6依1.2 17.6依0.4 19.1依0.6 4.0依0.7 3.7依0.7 3.0依0.4 2.8依0.3 3.5依0.9 3.5依0.6 4.1依0.5 3.4依0.4 4.0依0.4 3.3依0.3
Fe 17.4依0.7 17.2依0.9 15.1依1.6 17.5依0.7 15.6依0.8 4.4依0.5 4.9依0.8 3.3依0.6 4.4依0.5 4.0依0.8 2.9依0.3 2.5依0.3 2.1依0.4 2.2依0.3 2.0依0.2
195 N 16.1依1.1 15.7依0.7 16.2依0.7 16.0依0.3 16.1依0.4 3.0依0.5 2.3依0.2 4.0依0.8 3.3依0.2 2.8依0.4 2.8依0.2 3.0依0.3 2.8依0.2 3.0依0.2 3.4依0.2
Fe 18.3依1.3 19.5依0.3 17.7依1.2 14.6依1.0 16.0依1.3 3.9依1.0 6.0依0.2 4.5依1.5 2.4依0.7 6.3依1.6 3.4依0.3 2.9依0.5 3.2依0.5 2.4依0.5 2.6依0.2
240 N 14.7依0.4 16.6依0.6 14.9依0.8 16.0依0.5 15.3依1.1 1.6依0.2 2.0依0.2 3.3依1.3 4.1依2.5 1.6依0.1 4.2依0.5 1.1依0.4 4.1依0.3 4.0依0.3 4.1依0.2
Fe 14.8依0.7 14.5依0.3 12.8依0.9 12.7依1.0 11.8依1.5 5.0依0.2 5.9+0.2 7.4依3.5 7.3依1.5 5.0依0.6 5.2依0.9 2.9+0.5 5.2依1.6 3.8依0.5 4.3依0.5
Data are expressed as mean依SEM (n=20).
Table 2 
Blood chemistry values for the normal diet and Fe diet-fed mice treated with distilled water (DW), DFP and CM1 for 180 d. 
Days Diet AST activity (IU/L) ALT activity (IU/L) ALP activity (IU/L)
DW DFP 
50 mg/
kg
CM1 
50 mg/kg
CM1
100 mg/kg
CM1 
200 mg/kg
DW DFP 
50 mg/
kg
CM1 
50 mg/kg
CM1 
100 mg/
kg
CM1 
200 mg/
kg
DW DFP
50mg/kg
CM1 
50 mg/
kg
CM1
100mg/kg
CM1
200mg/kg
0 N  33依3 26依2 30依5 22依2 23依2 14依2 17依2 17依3 13依1 10依2 39依3 31依4 31依3 29依3 29依3
Fe  58依12 40依6 48依5 41依4 49依5 23依4 21依2 22依2 22依2 22依3 29依4 23依3 29依4 28依4 30依4
60 N  28依1 27依2 31依2 32依4 36依3 42依2 30依4 37依4 34依4 40依4 33依3 30依3 30依3 28依2 29依2
Fe  28依4 32依3 22依3 27依5 29依6  50依19   87依31   91依30   57依10  67依16 30依3 34依3 29依2 36依4 33依4
105 N  30依6 18依4 18依3 18依4 21依3 28依3  19依3 24依2 19依2 21依2 19依1 22依2 20依1 20依2 23依5
Fe  95依11 90依9 90依8 74依7   85依14   78依11  104依10 103依14 92依6 95依9 46依3 44依2 42依2 46依3 47依3
150 N  58依11   55依14 46依6 58依9 51依8 39依2  36依9 36依7 40依4 44依5 36依2 33依3 31依2 33依2 35依2
Fe  34依11   29依12 16依4   35依11   60依19   90依12  82依7   87依11 88依9 100依20 36依2 33依3 35依3 32依1 31依2
195 N  29依5 25依3 20依2 25依3 21依3 16依2  20依2 16依2 16依2 18依2 26依3 30依4 27依2 31依2 24依2
Fe  57依8 89依2  76依13 55依8 95依9  126依15  148依12   90依31 113依25 144依18 42依5 61依4 44依5 41依4 39依3
240 N  40依3 43依7 34依5  48依10 38依5  29依2  16依4 18依3 27依7 24依4 26依2 28依3 24依2 26依1 28依2
Fe  72依3 89依2 96依3 42依5  52依12 102依3 148依2 151依3  68依11 101依5 44依4 61依3 50依2 37依5 42依4
Data are expressed as mean依SEM (n=20).
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3.4. Effect of CM1 on liver cells
   To investigate whether CM1 damaged hepatocytes 
under normal and iron overloaded conditions, we 
investigated marker enzymes for liver damage including 
AST, ALT and ALP by using enzyme test kits based on 
spectrophotometric analysis. The results demonstrated no 
significant difference between placebo and treated mice 
in all enzymes under both dietary conditions. There were 
also no dose-related effects. In iron-overloaded group, 
ALT was slightly increased after 60 d and reached a peak 
at 195 d before dropping 45 d later (Table 2). However, the 
trend was not shown in the AST and ALP measurements. 
AST and ALP slightly increased after 60 d. Nevertheless, 
these changes were still not dose-dependent.
3.5. Histology
   The results of histopathology examination are shown 
in Figure 4. The mice treated with distilled water, DFP 
(50 mg/mL) and CM1 (50, 100 and 200 mg/kg) in non-
overloaded and iron-overloaded heart tissue did not 
show any significant pathological changes in all groups. 
However, the histology of the liver tissue under iron-
overloaded condition showed moderate degree of spotty 
necrosis particularly in the portal area and predominant 
neutrophils and lymphocytes associated with numerous 
hemosiderin-laden macrophages in hepatic sinusoids. 
The spleen tissue contained numerous hemosiderin-laden 
macrophages in both red and white pulp particularly in 
Fe diet group. The results suggested that CM1 was not 
toxic to tissue organs including heart, liver and spleen 
after administration over 180 d.
4. Discussion
   Although iron is required for a variety of cellular 
processes, it highly toxic because of its propensity to 
induce the production of dangerous free radicals resulting 
in oxidative cell damage and cell death[33,34]. Therefore, 
iron chelation therapy is required to remove excess iron. 
There is a wide range of clinically used iron chelators but 
none of these compounds are free from side effects. We 
have developed a new bidentate iron chelator, CM1 that is 
DFP analogue and also has higher lipophilicity (Kpart=0.53). 
To investigate the iron chelating activity and toxicity of 
CM1, mice were fed with 0.2 % (w/w) ferrocene in long-
term administration, inducing iron overload as determined 
by the significant increase of NTBI, LPI and ferritin levels 
Groups
None-overloaded
Organs
Heart
Liver
Spleen
Heart
Liver
Spleen
Overloaded
Distilled water DFP 50 mg/kg CM1 50 mg/kg CM1 100 mg/kg CM1 200 mg/kg
Figure 4. Representative pathological examination of the normatl diet and Fe diet-fed mice treated with distilled water, DFP (50 mg/kg) and CM1 (50, 100 and 
200 mg/kg) for 180 d.
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in the plasma. Chelation treatment with either DFP or CM1 
led to the reduction of NTBI and LPI levels in the iron-
overloaded mice. At the higher concentrations of 100 
and 200 mg/kg, CM1 was found to be more effective than 
when given at a concentration of 50 mg/kg. In contrast to 
the findings related to NTBI, serum ferritin levels were 
found to be unaffected by the presence of chelators. This 
finding reflects the observation that in some cases in 
β-thalassemia patients treated with iron chelators, the 
plasma ferritin levels are largely unchanged or are only 
reduced after prolonged iron chelator treatment[35].  
   Side effects of clinically used iron chelators have been 
reported. We therefore investigated the safety of CM1 in 
the mice under both normal and iron overload conditions. 
No significant difference in hemoglobin was found 
between placebos and treated groups with similar levels 
of white blood cells and platelets. The results indicated 
that CM1 did not affect peripheral blood cells, this may 
imply that CM1 treatment is free from side effects such as 
leukopenia and thrombocytopenia under normal and iron-
overloaded conditions. To identify any CM1 induced-
liver damage, we also investigated activity of AST, ALT 
and ALP. The results showed that the enzyme activities 
did not display any dose-dependency. The liver enzymes 
slightly increased after 60 d in all groups and peaked on 
Day 150, especially in iron overloaded mice, but there 
was still no difference between treated and placebo 
groups. These may be because high iron accumulation 
induces liver damage through generation of dangerous 
free radicals, resulting in liver damage and releasing of 
these enzymes[36]. During pathological examination of 
tissues, no significant pathological changes in the hearts 
were observed for normal and iron-loaded mice. The 
livers were composed of predominant neutrophil and 
lymphocytes in iron-loaded mice. This is probably due 
to liver being the major organ for iron accumulation that 
caused diffuse leucocyte infiltration[37,38]. The spleen 
presented numerous of scattered hemosiderin-laden 
macrophages especially in iron loaded mice. 
   In conclusion, CM1 is an orally active iron chelator. It is 
able to chelate iron effectively and also has no toxicity to 
peripheral blood and liver cells of the mice under normal 
and iron overload conditions. Whether these advantages 
can be transferred to the treatment of thalassemia 
patients remains to be established.
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